ASO treatment for spinal muscular atrophy was recently approved following successful clinical trials (Finkel et al., 2016) and ASOs are also in clinical trial for SOD1 ALS (Miller et al., 2013). This evidence concerns the gene SOD1 and proximal spinal muscular atrophy.